A significantly higher 120-days mortality after AZA was associated with ECOG ≥ 2 (OR 3.04, 95% CI 1.86–4.95), bone marrow blast count ≥ 50% (OR 1.91, 95% CI 1.17–3.09), high risk cytogenetic (OR 2.166, 95% CI 1.311–3.583), de novo vs. secondary AML (OR 0.62, 95% CI 0.39–0.97), adverse risk cytogenetic (OR 2.22, 95% CI 1.34–3.68), and TP53 mutated (OR 6.29, 95% CI 1.13–42.54). This evidence concerns the gene TP53 and acute myeloid leukemia.